% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{LeRhun:1032446,
      author       = {Le Rhun, Emilie and Albert, Nathalie L and Hüllner, Martin
                      and Franceschi, Enrico and Galldiks, Norbert and Karschnia,
                      Philipp and Minniti, Giuseppe and Weiss, Tobias and
                      Preusser, Matthias and Ellingson, Benjamin M and Weller,
                      Michael},
      title        = {{T}argeted radionuclide therapy for patients with {CNS}
                      metastasis: overlooked potential?},
      journal      = {Neuro-Oncology},
      volume       = {26},
      number       = {$Supplement_9$},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2024-06252},
      pages        = {noae192},
      year         = {2024},
      abstract     = {Targeted radionuclide therapy is an emerging therapeutic
                      concept for metastatic cancer that can be considered if a
                      tumor can be delineated by nuclear medicine imaging and also
                      targeted based on expression of a particular target
                      (thera-nostics). This mode of treatment can also compete
                      with or supplement conventional radiotherapy e.g., if MRI
                      does not fully capture the extent of disease, including
                      microscopic metastases. Targeted radionuclide therapy for
                      patients with thyroid cancer, with certain somatostatin
                      receptor 2-expressing tumors and with prostate-specific
                      membrane antigen (PSMA)-expressing prostate cancer are
                      approved, and numerous approaches of targeted radionuclide
                      therapy for patients with metastatic cancer are in
                      development (e.g. using fibroblast activation protein (FAP)
                      as a target). Although brain metastases are rare in the
                      cancers with approved targeted radionuclide therapies, there
                      is no a priori reason to assume that such treatments would
                      not be effective against brain metastases if the targets are
                      expressed and not shielded by the blood brain barrier. Here,
                      we discuss the current state of the art and opportunities of
                      targeted radionuclide therapies for patients with brain and
                      leptomeningeal metastases.Keywords: brain; leptomeningeal;
                      radioligand; radiopharmaceutical; target; theranostics.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {39351771},
      UT           = {WOS:001374738400004},
      doi          = {10.1093/neuonc/noae192},
      url          = {https://juser.fz-juelich.de/record/1032446},
}